朱凤才，江苏省疾病预防控制中心副主任，主任医师，博士生导师，享受国务院“政府特殊津贴”专家待遇，江苏省“333工程”第一层次培养对象，入选“国家百千万人才工程”，先后获得国家人事部、卫计委和江苏省“有突出贡献中青年专家”、“全国优秀科技工作者”等荣誉称号，2015年国际顶级刊物Lancet发表人物专访称为“中国疫苗评价引领者”。
主要从事传染病防控研究，作为主要研究者负责包括我国近年仅有的五种创新性疫苗在内的百余项疫苗临床评价，为我国从疫苗使用大国迈向研发大国做出了贡献；率领团队证实全球首例人感染H7N4禽流感病例。筛选制备多种针对多种病毒的全人源单克隆抗体，发明相关专利10余项，成功鉴定新冠病毒多个区域的中和抗体位点。主持科技重大专项、“863” 项目、国家自然科学基金等省部级以上课题5项；获省部级科技奖励9项，其中以第一完成人获得江苏省科学技术奖一等奖2项；发表论文400余篇，SCI收录100余篇，近年来连续在国际顶尖期刊《新英格兰医学杂志》发表论著3篇，《柳叶刀》发表论著10篇。
研究方向：疫苗临床评价、传染病防控
邮箱：jszfc@sina.vip.com
主要在研项目：
国家科技重大专项（2018ZX10715002）江苏省防治艾滋病、病毒性肝炎和结核病等重大传染病规模化现场流行病学和干预研究
代表性论文：
1.Feng-Cai Zhu, Hua Wang, Han-Hua Fang, Jian Guo Yang, Xiao Jun Lin, Xiao-Feng Liang, Xue-Feng Zhang, Hong-Xing Pan, Fan-Yue Meng, Yue Mei Hu, Wen-Dong Liu, Chang-Gui Li, Wei Li, Xiang Zhang, Jin Mei Hu, Wei Bing Peng, Bao Ping Yang, Pei Xi, Hua-Qing Wang, Jing-Shan Zheng.A Novel Influenza A (H1N1) Vaccine in Various Age Groups[J]. NEJM, 2009, 361(25):2414-2423.（第一作者和独立通讯作者）
2.Feng-Cai Zhu, Yu-Hua Li*, Xu-Hua Guan, Li-Hua Hou, Wen-Juan Wang, Jing-Xin Li, Shi-Po Wu, Bu-Sen Wang, Zhao Wang, Lei Wang, Si-Yue Jia, Hu-Dachuan Jiang, Ling Wang, Tao Jiang, Yi Hu, Jin-Bo Gou, Sha-Bei Xu, Jun-Jie Xu, Xue-Wen Wang, Wei Wang, Wei Chen. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial[J].Lancet, 2020, https://doi.org/10.1016/ S0140-6736(20)31208-3.（第一作者和共同通讯作者）
3.Fengcai Zhu, Wenbo Xu, Jielai Xia, Zhenglun Liang, Yan Liu, Xuefeng Zhang, Xiaojuan Tan, Ling Wang, Qunying Mao, Junyu Wu, Yuemei Hu, Tianjiao Ji, Lifei Song, Qi Liang, Baomin Zhang, Qiang Gao, Jingxin Li, Shenyu Wang, Yuansheng Hu, Shanru Gu, Jianhua Zhang...Junzhi Wang*,Hua Wang*, Nan Wang*.Efficacy, safety, and immunogenicity of an enterovirus71vaccinein China[J]. NEJM,2014, 370(9), 818-828.（第一作者）
4.Jun Zhang*, Xue-Feng Zhang, Shou-Jie Huang, Ting Wu, Yue-Mei Hu, Zhong-Ze Wang, Hua Wang, Han-Min Jiang, Yi-Jun Wang, Qiang Yan, Meng Guo, Xiao-Hui Liu, Jing-Xin Li, Chang-Lin Yang, Quan Tang, Ren-Jie Jiang, Hui-Rong Pan, Yi-Min Li, J. Wai-Kuo Shih, Mun-Hon Ng, Feng-Cai Zhu, and Ning-Shao Xia .Long-term efficacy of a hepatitis E vaccine[J]. N Engl J Med. 2015, 372(10):914-922. (共同通讯作者)
5.Feng-Cai Zhu, Zheng-Lun Liang, Xiu-Ling Li, Heng-Ming Ge, Fan-Yue Meng, Qun-Ying Mao, Yun-Tao Zhang, Yue-Mei Hu, Zhen-Yu Zhang, Jing-Xin Li,Fan Gao, Qing-Hua Chen, Qi-Yan Zhu, Kai Chu, Xing Wu, Xin Yao, Hui-Jie Guo, Xiao-Qin Chen, Pei Liu, Yu-Ying Dong, Feng-Xiang Li, Xin-Liang Shen, Jun-Zhi Wang. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial[J]. Lancet, 2013, 381(9871):1037-1045.(第一作者)
6.Feng-Cai Zhu, Fan-Yue Meng, Jing-Xin Li, Xiu-Ling Li, Qun-Ying Mao, Hong Tao, Yun-Tao Zhang, Xin Yao, Kai Chu, Qing-Hua Chen, Yue-Mei Hu, Xing Wu, Pei Liu, Lin-Yang Zhu, Fan Gao, Hui Jin, Yi-Juan Chen, Yu-Ying Dong, Yong-Chun Liang, Nian-Min Shi, Heng-Ming Ge...Zheng-Lun Liang*, Xin-Liang Shen. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet. 2013, 381(9882): 2024-2032. (第一作者和共同通讯作者)
7.Feng-Cai Zhu, Jun Zhang, Xue-Feng Zhang, Cheng Zhou, Zhong-Ze Wang, Shou-Jie Huang, Hua Wang, Chang-Lin Yang, Han-Min Jiang, Jia-Ping Cai, Yi-Jun Wang, Xing Ai, Yue-Mei Hu, Quan Tang, Xin Yao, Qiang Yan, Yang-Ling Xian, Ting Wu, Yi-Min Li, Ji Miao, Mun-Hon Ng, James Wai-Kuo Shih, Ning-Shao Xia. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial[J]. Lancet, 2010, 376(9744):895-902.（第一作者）
8.Ming Zeng, Xu-Hu Mao, Jing-Xin Li, Wen-De Tong, Bin Wang, Yi-Ju Zhang, Gang Guo, Zhi-Jing Zhao, Liang Li, De-Lin Wu, Dong-Shui Lu, Zhong-Ming Tan, Hao-Yu Liang, Chao Wu, Da-Han Li, Ping Luo, Hao Zeng, Wei-Jun Zhang, Jin-Yu Zhang, Bo-Tao Guo, Feng-Cai Zhu, Quan-Ming Zou. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2015, 386(10002):1457-1464. (共同通讯作者)
9. Feng-Cai Zhu, Li-Hua Hou, Jing-Xin Li, Shi-Po Wu, Pei Liu, Gui-Rong Zhang, Yue-Mei Hu, Fan-Yue Meng, Jun-Jie Xu, Rong Tang, Jin-Long Zhang, Wen-Juan Wang, Lei Duan, Kai Chu, Qi Liang, Jia-Lei Hu, Li Luo, Tao Zhu, Jun-Zhi Wang, Wei Chen. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet, 2015, 385(9984):2272-2279. (第一作者)
10. Zhu Feng-Cai,Wurie Alie H,Hou Li-Hua,Liang Qi,Li Yu-Hua,Russell James B. W.,Wu Shi-Po,Li Jing-Xin,Hu Yue-Mei,Guo Qiang , Xu Wen-Bo,Wurie Abdul R,Wang Wen-Juan,Zhang Zhe,Yin Wen-Jiao,Ghazzawi Manal,Zhang Xu,Duan Lei,Wang Jun-Zhi,Chen Wei. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2017, 389(10069):621-628.（第一作者）